TIL vs. CRMD, RNAC, TKNO, TERN, VERV, MGTX, PRTC, ARCT, ABVX, and ZVRA
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include CorMedix (CRMD), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), Terns Pharmaceuticals (TERN), Verve Therapeutics (VERV), MeiraGTx (MGTX), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), ABIVAX Société Anonyme (ABVX), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.
Instil Bio vs.
Instil Bio (NASDAQ:TIL) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
Instil Bio has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.
In the previous week, CorMedix had 3 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for CorMedix and 0 mentions for Instil Bio. CorMedix's average media sentiment score of 1.84 beat Instil Bio's score of 0.00 indicating that CorMedix is being referred to more favorably in the news media.
Instil Bio presently has a consensus target price of $145.00, suggesting a potential upside of 603.54%. CorMedix has a consensus target price of $15.80, suggesting a potential upside of 93.15%. Given Instil Bio's higher possible upside, equities analysts clearly believe Instil Bio is more favorable than CorMedix.
Instil Bio received 76 more outperform votes than CorMedix when rated by MarketBeat users. However, 74.19% of users gave CorMedix an outperform vote while only 50.25% of users gave Instil Bio an outperform vote.
Instil Bio's return on equity of -37.44% beat CorMedix's return on equity.
CorMedix has higher revenue and earnings than Instil Bio. CorMedix is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 46.5% of Instil Bio shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Instil Bio and CorMedix tied by winning 8 of the 16 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Instil Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TIL) was last updated on 1/5/2025 by MarketBeat.com Staff